New Prognostic Markers in Acute Myeloid Leukemia (AML)

Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML

A Prognostic Model for MDS that Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS)

Three Alternate Dosing Schedules of Azacitidine for MDS

EORTC-06011: Low-Dose Decitabine versus Best Supportive Care for Elderly Patients with Intermediate- or High-Risk MDS

Myelodysplastic Syndromes

Azacitidine Before Allogeneic Hematopoietic Cell Transplantation (AHCT) for Myelodysplasias

Anthracycline Dose Intensification in Acute Myeloid Leukemia (AML)

Outcome of Myelodysplastic Syndrome (MDS) with and without
Chromosome 5 Abnormalities

Efficacy of Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS)

Cooked and Noncooked Diets in Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Pazopanib in Patients with Treatment-Naïve or Cytokine-Pretreated Advanced RCC

Sunitinib Continuous 37.5 mg/Day Dosing in Cytokine-Refractory Metastatic RCC

Everolimus in Patients with Cytokine-Pretreated mRCC

Presurgical Feasibility of Bevacizumab for Nephrectomy-Eligible, Treatment-Naïve Patients with Metastatic Renal Cell Carcinoma